Swiss pharma firm Idorsia plans debt restructuring, job cuts in profitability drive

BY Reuters | CORPORATE | 11/27/24 02:18 AM EST

ZURICH, Nov 27 (Reuters) - Idorsia plans to restructure its debt, implement cost-cutting measures and could shed up to 270 jobs in a bid to spur profitability, the Swiss pharma company said on Wednesday.

Idorsia, which posted a net loss of 180 million Swiss francs ($203 million) for the first nine months of 2024, said it aims to conclude the restructuring by the end of the year, with the cost reductions fully effective by the second quarter of 2025.

The shake-up plan includes steps to restructure the company's outstanding debt, CEO Andre Muller said.

"I am confident that our plan is achievable within the next few months, and that will allow us to shift our focus back to our products," he said.

To reach sustainable profitability, the company said it must focus efforts, reducing the number of active projects in research and development and preparing some for out-licensing.

To this end, it plans to cut staffing levels and said that depending on the outcome of a consultation process, about 270 positions globally could become redundant, mainly in research and development and support functions at headquarters.

According to its website, the company has over 750 employees.

($1 = 0.8854 Swiss francs) (Writing by Dave Graham, Editing by Miranda Murray)

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article